Skip to main navigation
Skip to content

Salarius

Live - Corporate Menu

  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
    • Scientific Advisors
  • Our Programs
    • Epigenetics
    • Targeted Protein Degradation
    • Pipeline
    • Publications
    • Clinical Trials
  • News & Events
    • Press Releases
    • Upcoming Events
    • In the News
  • Investors
    • Overview
    • Corporate Governance
      • Governance Highlights
      • Committee Composition
    • Press Releases
    • In The News
    • Financial Reports
      • Annual Reports
      • Quarterly & Other Reports
      • Tax Documents
    • SEC Filings
    • Events & Presentations
    • Investor Resources
      • Investor FAQS
      • Information Request
      • E-Mail Alerts
      • Contact IR
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Price Lookup
    • Analyst Coverage
  • Contact Us
Search

IN THE NEWS

IN THE NEWS

SNN Network

Salarius CEO, David Arthur discusses the future of the company with SNN Network

The Fly

Salarius, Aspire Capital announce a $10.9M stock purchase agreement

Houston Business Journal

Houston pharma co. lands nearly $11M investment from Chicago group

WuXi AppTec

Salarius Believes Children Should Not Be Left Behind in the Fight Against Cancer

Biotuesdays

David Arthur discusses Seclidemstat with Bio Tuedays

NASDAQ

Salarius’ CEO David Arthur Nasdaq Introduction

Globe Newswire

Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell

TD Ameritrade

Salarius’ CEO David Arthur on the Fight Against Cancer

NASDAQ

SALARIUS PHARMACEUTICALS, INC. RINGS THE NASDAQ STOCK MARKET OPENING BELL

Health Professional Radio

Phase 1 Trial for the Treatment of Ewing Sarcoma – Salarius Pharmaceuticals

TheFly.com

TheFly Speaks with Salarius CEO David Arthur

Pharmaceutical Executive

Biopharmaceutical Enterprises Pursuing Unconventional Paths to Public Markets

Pharmaceutical Executive

Houston oncology co. aims to grow after merger announcement

Houston Business Journal

Houston oncology co. to merge with Boston’s struggling Flex Pharma

Houston Chronical

Houston-based Salarius to merge with Flex Pharma

Houston Business Journal

Pharma company to relocate to Houston following CPRIT grant

Investor Tools

Salarius

Footer Nav

  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
    • Scientific Advisors
  • Our Programs
    • Epigenetics
    • Targeted Protein Degradation
    • Pipeline
    • Publications
    • Clinical Trials
  • News & Events
    • Press Releases
    • Upcoming Events
    • In the News
  • Investors
    • Overview
    • Corporate Governance
    • Press Releases
    • In The News
    • Events & Presentations
    • Financial Reports
    • Investor Resources
    • Stock Information
    • Analyst Coverage
  • Contact Us

Live - Social Icons

  • Connect on Facebook
  • Connect on Twitter
  • Connect on Linkedin
© 2023 Salarius Pharmaceuticals, Inc. All Rights Reserved.

Live - Footer

  • Privacy and Terms of Use